KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kodiak Sciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$91.35+5.60 (+6.53%)
Close on Oct 19, 2026
- Market cap
- $5.72B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$77.25 (+547.9%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.72B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 93.64
- Dividend yield
- –
- Free cash flow yield
- -2.79%
Fundamentals
- Net income
- -$241.99M
- EPS, diluted
- -$4.19
- Free cash flow
- -$159.90M
- Book value per share
- $0.98
- Diluted shares
- 63M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Operating income
-$246.42M
Net income
-$241.99M
EPS, diluted
-$4.19
Free cash flow
-$159.90M
Reported periodTrailing twelve months